Polaris Pharma (6550.TW) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Polaris Pharma is a clinical-stage biotech focused on developing first-in-class amino acid deprivation therapies for ASS1-deficient cancers. Its lead asset, ADI-PEG 20, has demonstrated pivotal Phase 3 success in malignant pleural mesothelioma and is under rolling BLA submission with the FDA, positioning the company for a potential near-term commercial launch. The strategy involves expanding the drug's utility across multiple oncology indications and exploring combinations with chemotherapy and immunotherapy to maximize its therapeutic and market potential.

OncologyMetabolic Disease

Technology Platform

Amino acid deprivation therapy targeting arginine auxotrophy in ASS1-deficient cancers via the pegylated enzyme pegargiminase (ADI-PEG 20).

Opportunities

First regulatory approval in mesothelioma provides a near-term commercial catalyst and validates the platform.

Expansion into larger oncology markets like sarcoma and HCC represents a multi-billion dollar opportunity.

The NASH program offers a potential non-oncology blockbuster indication.

Risk Factors

Execution risk in first-time commercialization and regulatory review.

High financial burn rate and dependence on equity markets for funding.

Pipeline concentration on a single asset, ADI-PEG 20.

Competitive Landscape

First-in-class in systemic arginine deprivation therapy with no direct approved competitors. Competes with standard chemo/immunotherapy regimens in each indication. Strong IP and first-mover clinical data provide a competitive moat.

More companies in Oncology (General) →More companies in United States →